Baxalta, now part of Shire, Canadian Hemophilia Epidemiological Research Program
The goal of the Baxalta, now part of Shire, Canadian Hemophilia Epidemiological Research Program (B-CHERP) is to provide Canadian investigators with new resources to conduct quality population-based clinical research in hereditary bleeding disorders in Canada. It is hoped that proposals will capitalize on the existing network of comprehensive care hemophilia clinics throughout Canada and assets such as the Canadian Bleeding Disorder Registry (CBDR). However, this will not be a limiting condition. The importance of supporting new investigators and of consolidating the research careers of young investigators will be considered when evaluating proposals.Application Cycle: New Grants and Renewals
Calls for applications will go out in JUNE 2017 with a deadline for submission of August 30th 2017. Apply here
The results of the competition will be announced by October 1st and funding will be disbursed in December 2017. Candidates that are applying for the renewal of a grant already funded also have until August 30th 2017 to submit updated results to support continued funding in 2017.New Grants Available in 2017
B-CHERP will fund one new research proposal in 2017 with a maximum grant of $75,0000 for the first year, renewable annually for up to a total of 3 years. Two proposals may be funded if the sums requested are less than $75,000 in the first year.BAXALTA, NOW PART OF SHIRE, PARTNERSHIP WITH AHCDC
Since 2005 Baxalta, now part of Shire, and the Association of Hemophilia Clinic Directors of Canada (AHCDC) have entered into a partnership to advance hemophilia research in Canada.RESEARCH TYPE & SCOPE
The program will support and fund clinical, descriptive and epidemiological studies of hereditary bleeding disorders. While inquiries of correlations between clinical and biological or genetic determinants are expected, the program will not support strictly fundamental research. For the purpose of this program, hereditary bleeding disorders include hemophilia A and B including inhibitor patients, Von Willebrand disease, and other rare inherited bleeding disorders. The importance of supporting new investigators and of consolidating the research careers of young investigators will be considered when evaluating proposals.